EI

281.1

+0.25%↑

SAN

86.18

+1.07%↑

MRK1

119.3

-0.83%↓

SHL.DE

47.04

+1.1%↑

UCB

251

+1.29%↑

EI

281.1

+0.25%↑

SAN

86.18

+1.07%↑

MRK1

119.3

-0.83%↓

SHL.DE

47.04

+1.1%↑

UCB

251

+1.29%↑

EI

281.1

+0.25%↑

SAN

86.18

+1.07%↑

MRK1

119.3

-0.83%↓

SHL.DE

47.04

+1.1%↑

UCB

251

+1.29%↑

EI

281.1

+0.25%↑

SAN

86.18

+1.07%↑

MRK1

119.3

-0.83%↓

SHL.DE

47.04

+1.1%↑

UCB

251

+1.29%↑

EI

281.1

+0.25%↑

SAN

86.18

+1.07%↑

MRK1

119.3

-0.83%↓

SHL.DE

47.04

+1.1%↑

UCB

251

+1.29%↑

Search

Genfit

Aperta

SettoreSettore sanitario

3.51 1.39

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.408

Massimo

3.552

Metriche Chiave

By Trading Economics

Entrata

-29M

Vendite

8M

P/E

Media del settore

104.267

35.739

Margine di Profitto

-358.75

Dipendenti

188

EBITDA

-24M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+149.22% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

164M

Apertura precedente

2.12

Chiusura precedente

3.51

Notizie sul Sentiment di mercato

By Acuity

39%

61%

112 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Genfit Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 ott 2025, 23:30 UTC

Azioni calde

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 ott 2025, 21:21 UTC

Utili

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 ott 2025, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 ott 2025, 23:40 UTC

Discorsi di Mercato

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 ott 2025, 23:39 UTC

Discorsi di Mercato

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 ott 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 ott 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 ott 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 ott 2025, 23:00 UTC

Discorsi di Mercato

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 ott 2025, 22:54 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Scales's JV Buyout Lauded by Bull -- Market Talk

2 ott 2025, 22:54 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Forex and Fixed Income Roundup: Market Talk

2 ott 2025, 22:46 UTC

Discorsi di Mercato

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 ott 2025, 22:46 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

2 ott 2025, 21:17 UTC

Acquisizioni, Fusioni, Takeovers

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 ott 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Energy & Utilities Roundup: Market Talk

2 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

2 ott 2025, 20:49 UTC

Acquisizioni, Fusioni, Takeovers

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 ott 2025, 20:00 UTC

Acquisizioni, Fusioni, Takeovers

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 ott 2025, 19:20 UTC

Discorsi di Mercato

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 ott 2025, 19:10 UTC

Discorsi di Mercato

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 ott 2025, 19:04 UTC

Discorsi di Mercato

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 ott 2025, 18:46 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 ott 2025, 18:46 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 ott 2025, 18:46 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 ott 2025, 18:45 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 ott 2025, 18:45 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 ott 2025, 18:44 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 ott 2025, 18:44 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 ott 2025, 18:44 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 ott 2025, 18:43 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Confronto tra pari

Modifica del prezzo

Genfit Previsione

Obiettivo di Prezzo

By TipRanks

149.22% in crescita

Previsioni per 12 mesi

Media 8.399 EUR  149.22%

Alto 8.4 EUR

Basso 8.4 EUR

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Genfit - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

1

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

3.566 / 4.12Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

112 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
help-icon Live chat